Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux

Thrombosis and Haemostasis

Volumn 93, Issue 5, 2005, Pages 999-1000

  Kuo, Kevin H M ^a   Kovacs, Michael J ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; DRUG HALF LIFE; FEMALE; GANGRENE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INJECTION SITE REACTION; PRIORITY JOURNAL; SIDE EFFECT; SKIN BRUISING; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT OUTCOME;

EID: 18844385757     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616573     Document Type: Article

References (20)

1. Kelton JG. Heparin-induced thrombocytopenia: an overview. Blood Rev 2002; 16: 77-80.
2. Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 2003; 101: 31-7.
3. Pravinkumar E, Webster NR. HIT/HITT and alternative anticoagulation: current concepts. Br J Anaesth 2003; 90: 676-85.
4. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535-55.
5. Gallus AS, Coghlan DW. Heparin pentasaccharide. Curr Opin Hematol 2002; 9: 422-9.
6. Petitou M, Herault JP, Bernat A, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999; 398: 417-22.
7. Keam SJ, Goa KL. Fondaparinux sodium. Drugs 2002; 62: 1673-85.
8. Amirail J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8: 114-7.
9. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 535-40.
10. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106: 629-35.
11. Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-12.
12. Arocas V, Bock SC, Raja S, et al. Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J Biol Chem 2001; 276: 43809-17.
13. Visentin GP, Moghaddam M, Beery SE, et al. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001; 138: 22-31.
14. Savi P, Chong B, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent anti-platelet antibodies. A blinded comparative multicenter study with unfractionated heparin. Blood 2003; 102: 319a.
15. Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm 2001; 58 Suppl 2: S14-S17.
16. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators. Circulation 2000; 102: 2726-31.
17. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-20.
18. Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-6.
19. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
20. Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.